Clopidogrel activities in patients with renal function impairment

Clinical Drug Investigation

Volumn 16, Issue 4, 1998, Pages 319-328

  Deray, Gilbert ^a   Bagnis, C ^a   Brouard, Rémi ^b   Necciari, José ^b   Leenhardt, Anne F ^b   Raymond, Françoise ^a   Baumelou, Alain ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DIPHOSPHATE; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; CREATININE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BLEEDING TIME; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE CLEARANCE; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; DRUG URINE LEVEL; FEMALE; HUMAN; KIDNEY FAILURE; MALE; METABOLITE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION;

EID: 0031771162     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-199816040-00006     Document Type: Article

References (21)

1. Harter HR, Burch JW, Majerus PW, et al. Prevention of thrombosis in patients on haemodialysis by low-dose aspirin. N Engl JMed 1979; 301: 577-9
2. Raine AEG. Hypertension, blood viscosity and cardiovascular morbidity in renal failure: implications of erythropoietin therapy. Lancet 1988; I: 97-100
3. Livio M, Benigni A, Begnis R, et al. Differential inhibition of platelet thromboxane and renal prostaglandins in the rat. J Pharmacol ExpTher 1989; 248: 334-41
4. Steiner RW, Coggins C, Carvalho ACA. Bleeding time in uremia: a useful test to assess clinical bleeding. Am J Hematol 1979; 7: 107-17
5. di Minno G, Martinez J, McKean M-L, et al. Platelet dysfunction in uremia: multifaceted defect partially corrected by dialysis. Am J Med 1985; 79: 552-9
6. Gaspari F, Vigano G, Orisio S, et al. Aspirin prolongs bleeding time in uraemia by a mechanism distinct from platelet cyclooxygenease inhibition. J Clin Invest 1987; 79: 1788-95
7. Livio M, Benigni A. Vigano G, et al. Moderate dose of aspirin and risk of bleeding in renal failure. Lancet 1986; 1: 414-6
8. Tabuchi N, Huet RCG, Sturk A, et al. Aprotinin preserves hemostasis in aspirin-treated patients undergoing cardiopulmonary bypass. Ann Thorac Surg 1994; 58: 1036-9
9. Herbert J-M, Frehel D, Vallée E, et al. Clopidogrel, a novel antiplatelet and antithrombotic agent. Cardiovasc Drug Rev 1993; 11: 180-98
10. Deray G, Brouard R, Bagnis C, et al. Safety and activity of clopidogrel, an antiplatelet agent, in chronic renal failure patients [abstract]. J Am Soc Nephrol 1996; 6: 384
11. Lowe GDO, Rumley A, Griffiths P, et al. Dose-dependent inhibition of platelet aggregation in healthy volunteers by a new agent, SR 25990c. Thromb Haemost 1989; 62: 414
12. Caplain H, Kieffer G, Thiercelin JF, et al. Tolerance and clinical pharmacology of repeated administration of clopidogrel (SR 25990c), a new antiplatelet agent, at three dose levels in normal healthy volunteers. Thromb Haemost 1989; 62: 410
13. Pharmacodynamics and pharmacokinetics of the novel antiplatelet agent, clopidogrel, in the young and the elderly with and without symptomatic atherosclerosis [abstract P916]. In: Guillin M-C, Bonnet G, Sissmann J, et al., editors. Eur Heart J 17: Abstract Supplement for the XVIIIth Congress of the European Society of Cardiology, Birmingham, UK, 25-29 August 1996; 161
14. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348: 1329-39
15. Born GVR. Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature 1962; 194: 927-9
16. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41
17. Thébault JJ, et al. Mesure du temps de saignement par la méthode d'Ivy-Nelson: un moyen de surveillance des thérapeutiques antiaggrégantes. Feuillets Biol 1979; 20: 41-2
18. Hass WK, Easton JD, Adams HP, et al. for the Ticlopidine Aspirin Stroke Study Group. A randomised trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients (TASS). N Engl J Med 1989; 321: 501-7
19. Roald HE, Barstad RM, Kierulf P, et al. Clopidogrel - a platelet inhibitor which inhibits thrombogenesis in non-anticoagulated human blood independently of the flow conditions. Thromb Haemost 1994; 71: 655-62
20. Clopidogrel compatibility with cardiac co-medicalion: studies of interactions with a beta-blocker, a calcium uptake antagonist and a cardiac glycoside. In: Cariou R, Peelers PAM, Forbes CD, et al., editors. Clin Pharmacol. In press
21. Necciari J. 1996. Internal report